Ticker Launch

SPAC · Merger completed

BCTG Acquisition Corp.

Business combination with Tango Therapeutics, Inc.

BCTG Acquisition Corp. is a blank-check company (SPAC) that raised $145M in its initial public offering on Sep 4, 2020, listing on Nasdaq Capital Market. It completed its business combination with Tango Therapeutics, Inc. on Aug 10, 2021; the combined company is Tango Therapeutics, Inc. (TNGX). G.D. Searle & Company led the IPO, with Schering-Plough and Array BioPharma. Loeb & Loeb advised the SPAC and Kirkland & Ellis advised the underwriters on the IPO.

Tango Therapeutics is a biotechnology company discovering drug targets and developing precision medicines for people with cancer. It uses synthetic lethality to develop therapies aimed at driver genes, focusing on tumor suppressor gene loss and cancer cells' ability to evade the immune system.

Status
Merger completed
IPO date
Sep 4, 2020
IPO size
$145M
IPO exchange
Nasdaq Capital Market
Target
Tango Therapeutics, Inc. (Legacy)
Announced
Apr 14, 2021
Closed
Aug 10, 2021
Combined company
Tango Therapeutics, Inc. (TNGX)
IPO underwriters
G.D. Searle & Company, Schering-Plough and Array BioPharma
SPAC counsel (IPO)
Loeb & Loeb
Underwriters' counsel (IPO)
Kirkland & Ellis

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2021